In contrast, Lefort et al. argue that knocking the CXCR4/CXCL12 pathway with AMD3100 and TN14003 does not reduce tumor growth and can even increase tumor spread in TNBC [96] AMD3100 reverses tamoxifen resistance by decreasing phosphorylated (p)-AKT levels of tamoxifen-resistant cells and a combination of Tamoxifen and AMD3100 could be efficacious in the treatment of tamoxifen resistance [97]. The gene discussed is CXCR4; the disease is neoplasm.